NDATOPICALCREAM
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TWYNEO is a fixed-dose combination cream containing tretinoin (a retinoid) and benzoyl peroxide for topical treatment of acne. The formulation combines retinoid activity with antimicrobial and keratolytic benefits to address multiple pathogenic factors in acne. This is a small-molecule topical dermatology product approved for patients seeking standardized combination therapy.
$0.052MPart D
Peak14.6 years to LOEEarly-stage peak-lifecycle product with minimal Part D penetration signals opportunity for commercial team expansion and market development initiatives.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TWYNEO represents a stable peak-lifecycle dermatology asset with strong patent protection through 2041, offering mid-career professionals sustained commercial and medical affairs opportunities in a specialty therapeutic area. Early market penetration (evidenced by low Part D claims) suggests aggressive growth phase ahead, creating openings for sales, marketing, and medical strategy roles focused on dermatologist engagement and patient adoption.
Brand Manager
Worked on TWYNEO at Mayne Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.